Global Rank
#31488
Country Rank
#203
Market Cap
$42.21 M
Price
$2.61
Change (%)
0.00%
Volume
18,306
Mabion S.A.'s latest marketcap:
$42.21 M
As of 08/14/2025, Mabion S.A.'s market capitalization has reached $42.21 M. According to our data, Mabion S.A. is the 31488th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | $42.21 M |
| Revenue (ttm) | $10.38 M |
| Net Income (ttm) | $-10,757,092.59 |
| Shares Out | 16.16 M |
| EPS (ttm) | $-0.67 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 09/12/2025 |
Market Cap Chart
Data Updated: 08/14/2025
Mabion S.A.'s yearly market capitalization.
Mabion S.A. has seen its market value drop from zł426.49 M to zł153.54 M since 2014, representing a total decrease of 64.00% and an annual compound decline rate (CAGR) of 9.17%.
| Date | Market Cap(zł) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/14/2025 | zł153.54 M | $42.21 M | 7.42% | 31488 |
| 12/30/2024 | zł143.84 M | $34.75 M | -50.96% | 30485 |
| 12/29/2023 | zł293.35 M | $74.37 M | -13.57% | 25069 |
| 12/30/2022 | zł339.41 M | $77.32 M | -65.63% | 23946 |
| 12/30/2021 | zł987.46 M | $244.35 M | 246.59% | 17675 |
| 12/30/2020 | zł284.9 M | $76.25 M | -73.03% | 22220 |
| 12/30/2019 | zł1.06 B | $277.12 M | -11.09% | 13151 |
| 12/28/2018 | zł1.19 B | $317.16 M | -10.73% | 11489 |
| 12/29/2017 | zł1.33 B | $381.56 M | 51.96% | 11743 |
| 12/30/2016 | zł875.91 M | $208.91 M | 67.14% | 12629 |
Company Profile
About Mabion S.A.
Mabion S.A. is a biotechnology company specializing in the development of innovative biotech drugs using monoclonal antibody technology. Headquartered in Konstantynów Łódzki, Poland, the company was established in 2007.
Core Activities
- Development of biopharmaceuticals for treating neoplastic, autoimmune, metabolic, and neurological diseases.
- Production and commercialization of advanced therapeutic solutions.
Key Products
- MabionCD20 – A targeted therapy for autoimmune and oncological conditions.
- MabionHER2 – A specialized treatment for HER2-positive cancers.
Frequently Asked Questions
-
What is Mabion S.A.'s (WSE-MAB) current market cap?As of 08/14/2025, Mabion S.A. (including the parent company, if applicable) has an estimated market capitalization of $42.21 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Mabion S.A. (WSE-MAB) rank globally by market cap?Mabion S.A. global market capitalization ranking is approximately 31488 as of 08/14/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.